PCMT1

Protein-L-isoaspartate(D-aspartate) O-methyltransferase · P22061 · PCMT1 on Sugi Atlas →

772 patent compounds predicted against PCMT1, 701 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ademetionine (SCHEMBL25176)	1.00	3/20
Ademetionine (SCHEMBL1300198)	1.00	3/20
Ademetionine (SCHEMBL1300205)	1.00	3/20
Ademetionine (SCHEMBL1980696)	0.98	3/20
Ademetionine (SCHEMBL4747876)	0.98	3/20
Ademetionine (SCHEMBL5465751)	0.88	3/20
Ademetionine (SCHEMBL7192080)	0.87	3/20
Ademetionine (SCHEMBL25177)	0.87	3/20
Ademetionine (SCHEMBL55479)	0.87	3/20
Ademetionine (SCHEMBL59293)	0.87	3/20
Ademetionine (SCHEMBL66767)	0.87	3/20
Ademetionine (SCHEMBL599664)	0.87	3/20
Ademetionine (SCHEMBL600368)	0.87	3/20
Ademetionine (SCHEMBL2007787)	0.87	3/20
Ademetionine (SCHEMBL3202538)	0.87	3/20
Ademetionine (SCHEMBL4164615)	0.87	3/20
Ademetionine (SCHEMBL7810282)	0.87	3/20
Ademetionine (SCHEMBL9518716)	0.87	3/20
Ademetionine (SCHEMBL9518725)	0.87	3/20
Ademetionine (SCHEMBL13033865)	0.87	3/20

Clinical trials — most relevant to PCMT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)	PHASE3	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Human Requirements for the Nutrient Choline	nan	COMPLETED
The Association Between LPCAT1 Genetic Polymorphism and Stress Biomarkers in Neonatal Respiratory Distress Syndrome	nan	UNKNOWN
At Home Ammonia Monitoring of Inborn Errors of Ammonia Metabolism	nan	RECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
KETO-TUMOR: a Study on Brain Tumors and Central Obesity	nan	RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders	nan	COMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease	nan	UNKNOWN
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients.	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
Proof of Concept Creatine Supplementation for Homocystinuria Study	nan	ACTIVE_NOT_RECRUITING
Epidemiology of Atherosclerosis	nan	COMPLETED
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD	nan	COMPLETED
Clinical and Laboratory Study of Methylmalonic Acidemia	nan	RECRUITING
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Biomarker for Creatine Deficiency Syndromes (BioCDS)	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a PCMT1 binder may also engage these)

Protein	Name	Similarity
Q4R5H0	—	1.000	Q4R5H0 →
P22062	—	1.000	P22062 →
P15246	—	1.000	P15246 →
Q5RA89	—	1.000	Q5RA89 →
Q5F3N1	—	1.000	Q5F3N1 →
P80895	—	1.000	P80895 →
P23506	—	1.000	P23506 →
Q92047	—	0.996	Q92047 →
Q42539	—	0.989	Q42539 →
Q43209	—	0.974	Q43209 →
GOT1	Aspartate aminotransferase, cytoplasmic	0.952	landscape →
P13221	—	0.951	P13221 →
Q5R691	—	0.950	Q5R691 →
A5A6K8	—	0.950	A5A6K8 →
P00504	—	0.949	P00504 →
A0A1F3	—	0.948	A0A1F3 →
Q5XGR8	—	0.947	Q5XGR8 →
Q27873	—	0.947	Q27873 →
Q9PW06	—	0.946	Q9PW06 →
Q4R5L1	—	0.946	Q4R5L1 →
P12886	—	0.946	P12886 →
P14674	—	0.946	P14674 →
LDHA	L-lactate dehydrogenase A chain	0.946	landscape →
Q98SL2	—	0.945	Q98SL2 →
A0A0K9RL25	—	0.945	A0A0K9RL25 →
Q42563	—	0.945	Q42563 →
Q9PT43	—	0.945	Q9PT43 →
Q99P39	—	0.945	Q99P39 →
O49543	—	0.945	O49543 →
Q6GML7	—	0.945	Q6GML7 →